Senda Biosciences Appoints Luke O’Neill, Ph.D., as Chief Scientific Officer
Senda Biosciences , Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.
- Senda Biosciences , Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.
- “Luke is a key addition to what is already a strong, effective leadership team,” said Guillaume Pfefer, Ph.D., Chief Executive Officer of Senda Biosciences and Partner at Flagship Pioneering.
- “Luke is a world-renowned immunologist who has contributed so much to the organization in his corporate governance and scientific advisory roles.
- He holds a Ph.D. in pharmacology from the University of London and conducted postdoctoral research at the University of Cambridge, UK.